33 results about "Diagnostic Specificity" patented technology

Featured are methods and systems to multiparametric non-linear dimension reduction (NLDR) methods for segmentation and classification of radiological images. Such methods for segmentation and classification of radiological images, includes pre-processing of acquired image data; and reconstructing the acquired image data using a non-linear dimension reduction technique so as to yield an embedded image representing all of the acquired, where the acquired image data comprises a plurality of different sets of image data of the same region of interest. Such NLDR methods and systems are particularly suitable for the ability to combine multiple input images into a single unit for increased specificity of diagnosis.

The present invention relates to CCP polypeptide and its application. CCP polypeptide is prepared through the following steps: calculating the hydrophilicity value, water treatment index and higher structure emergence frequency of amino acid, calculating the site with maximum antigenicity based on protein structure and thus obtaining synthetic peptide chain sequence SHQESTXGRSRGRSGRSGS; synthesizing in Fmoc chemical synthesis process with the said peptide chain the destination peptide of sequence HQCGQESTXGRSRGRSGRSGS. The enzyme-linked immunological method with the CCP peptide as antigen to detect rheumatoid arthritis is provided. The rheumatoid arthritis diagnosing kit has high diagnosis specificity, up to 80 %. The present invention has high early diagnosis rate on rheumatoid arthritis.

A universally usable method for specific detection of target nucleic acid sequences, which method can be performed very rapidly and also simply and furthermore which does not need any expensive instrumental systems. The method is intended to be suitable as a molecular genetic rapid test and to respect the requirements of diagnostic specificity assurance. In this regard it is important that only one specific amplification product be detected and that amplification artifacts can be unambiguously discriminated. A nucleic acid amplification kit suitable for performing this method.

The invention relates to a glioma typing system based on IDH1-R132H and ATRX expression. The system comprises: (1) glioma patients' tumor paraffin embedding kit and optional kit application instruction; (2) a kit for immunohistochemical detection of ATRX protein expression level of tumor of glioma patients and optional kit application instruction; and (3) a kit for immunohistochemical detection of IDH1-R132H protein expression in tumor of glioma patients and optional kit application instruction. When IDH1-R132H and ATRX losses are combined as diagnostic markers for distinguishing primary glioblastoma, WHO grading II/III oligodendroglioma, WHO grading II/III astrocytoma and secondary glioblastoma, diagnostic specificity is obviously higher than diagnostic specificity of the two single markers of IDH1-R132H or ATRX losses.

The invention creatively provides miR-192 serving as a specificity biomarker for early diagnosis of a diabetic kidney disease and application of the MiR-192. The adopted technical scheme is as follows: application of the miR-192 in the serum to the early clinical specificity diagnosis of the diabetic kidney disease uses qRT-PCR to detect miRNA-192 in the serum to diagnose the diabetic kidney disease; application of the miR-192 in the urine to the early clinical specificity diagnosis of the diabetic kidney disease uses qRT-PCR to detect miRNA-192 in the urine to diagnose the diabetic kidney disease, a critical point of the miRNA-192 used for diagnosing the early diabetic kidney disease is provided, application of the miRNA marker is used to prepare an early diagnosis agent or kit for detecting the diabetic kidney disease, and application of the miRNA marker is used to prepare an early diagnosis agent or kit for detecting the diabetic kidney disease. A novel diagnosis means is provided for the clinical diagnosis of the diabetic kidney disease, and the miR-192 and the application of the miR-192 have certain potential clinical values for the adjuvant treatment and the course monitoring of the diabetic kidney disease (DKD).

The invention provides a monoclonal antibody of human insulin-like growth factor binding protein-1, a monoclonal antibody host cell, a diagnostic reagent with the monoclonal antibody of the human insulin-like growth factor binding protein-1and a diagnostic reagent kit, wherein antigen of the monoclonal antibody is antigenic determinant of the human insulin-like growth factor binding protein-1; preferably, the antigenic determinant comprises an amino acid sequence represented by SEQIDNO:1; and the monoclonal antibody host cell contains the monoclonal antibody of the human insulin-like growth factor binding protein-1. The monoclonal antibody of the human insulin-like growth factor binding protein-1 can perform specific detection on the human insulin-like growth factor binding protein-1, and the prepared diagnostic reagent has high specificity of premature rupture of membrane diagnosis, rapid reaction, low cost and suitability for large-scale popularization and application.

The invention discloses a detection card for rapidly detecting micro ribonucleic acid (miRNA). The detection card comprises a sample pad, a nanomaterial pad, a nitrocellulose membrane and an absorbent pad, wherein the nitrocellulose membrane is a detection card substrate, a sample injection zone, a blank control zone and a sample detection zone are distributed on the detection card substrate, the sample injection zone is communicated with the sample detection zone, the blank control zone and the sample detection zone are modified with probes having miRNA sequences complementary to to-be-detected miRNA, one ends of the probes are connected with the detection card substrate, and the other ends of the probes carry fluorescent groups. The invention also discloses a preparation method of the detection card. The invention also discloses a kit for rapidly detecting the miRNA associated with lung cancer. The invention also discloses application of the detection card and the detection kit. The detection card has relatively high detection sensitivity on miRNA associated with lung cancer and can simultaneously detect a plurality of miRNAs without PCR, the clinical diagnostic specificity is improved and the detection card meets application requirements of screening, diagnosis of lung cancer, determination of treatment effect and follow-up visit.

The invention provides a circular RNA molecule marker circRNA 0002086 for detecting cerebral ischemia-reperfusion injury. According to the circular RNA molecule marker circRNA 0002086, a circRNA molecule marker diagnostic model is used for diagnosing the cerebral ischemia-reperfusion injury for the first time, the good diagnostic efficiency is achieved, serum level circRNA of the cerebral ischemia-reperfusion injury is detected through a real-time fluorescence quantification PCR technology, the quantification is accurate, and convenience and reliability are achieved; and the provided circRNA can be used for clinical diagnosis of the cerebral ischemia-reperfusion injury, the diagnostic specificity of the circRNA 0002086 reaches 87%. According to the circular RNA molecule marker circRNA 0002086 for detecting the cerebral ischemia-reperfusion injury, a foundation is laid for that the state of a patient with the cerebral ischemia-reperfusion injury is quickly and accurately grasped by clinical doctors, and the clinical therapeutic effect is improved, help is provided for finding of novel small molecule drug targets with potential therapeutic value, and the circular RNA molecule markercircRNA0002086 has good application value and prospects.

We have developed a modified indirect ELISA (MI-ELISA) using the spherical body protein-4 (SBP4) of Babesia bovis to detect antibody against diverse isolates through all infection stages in cattle. This SBP4 MI-ELISA was evaluated for sensitivity and specificity against field sera and sera from cattle infected experimentally with various doses and isolates as well as in detecting acute and persistent infection. The diagnostic specificity of the SBP4 MI-ELISA using IFA-negative sera was 100%, significantly higher than the RAP-1 cELISA (90.4%); the diagnostic sensitivity of the SBP4 MI-ELISA was 98.7% using the IFA-positive sera, in contrast to that of the RAP-1 cELISA at 60%. Results demonstrate excellent diagnostic sensitivity and specificity of the novel SBP4 MI-ELISA for cattle with acute and long-term carrier infections. Use of the SBP4 MI-ELISA assay in countries that have B. bovis-endemic herds will be pivotal in preventing the spread of this disease to non-endemic herds.

The invention provides a detection method of specific gamma-glutamyl transferase, which specifically detects the activity difference of the gamma-glutamyl transferase in serum before and after forming an immunoprecipitation bonder between an anti-apolipoprotein B antibody and low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL); as well as a diagnostic reagent or a diagnostic kit prepared by applying the method. Compared with the prior art, the invention provides a simple and effective diagnostic reagent or diagnostic kit for diagnosis or auxiliary diagnosis of liver cancer. Experiment results show that the specific method for detecting the activity of LDL/VLDL-GGT (gamma-glutamyl transferase) in the serum, provided by the invention, can be used for the diagnostic reagent or the diagnostic kit for detection or auxiliary detection of liver cancer, the average diagnostic specificity can be more than 70%, and the average positive predictive value is 90%. Therefore, the application prospects of the invention are very broad.

The invention relates to a FISH probe and kit for identifying peripheral blood circulation tumor cells (CTCs) of a urothelial carcinoma patient, belonging to the field of biomedicine. The FISH probe for identifying peripheral blood CTCs of a urothelial carcinoma patient contains a chromosome 3 centromere and a chromosome 7 centromere. The kit contains the probe. By utilizing the genetic characteristics of urothelial carcinoma in combination with the diagnosis specificity of the chromosome 3 and chromosome 7, the FISH probe is utilized to label the peripheral blood enriched CTCs, thereby implementing accurate counting and identification on the urothelial carcinoma CTCs, and lowering the unnecessary waste of time, human resources and cost.

The invention discloses application of serum GSDME in diagnosis, curative effect monitoring and prognosis evaluation of B lymphocytic leukemia. The invention provides application of serum GSDME in preparation of a kit for diagnosing B lymphocytic leukemia and/or monitoring the curative effect of B lymphocytic leukemia and/or evaluating the prognosis of B lymphocytic leukemia. The kit contains a reagent for detecting the expression level of GSDME in serum and/or plasma. By establishing an immunological detection method of serum (plasma) GSDME, what is verified is that the serum (plasma) GSDME has good diagnostic specificity and sensitivity to B lymphocytic leukemia, and what is verified is that serum GSDME has important clinical application value in treatment effect monitoring and prognosis evaluation of B lymphocytic leukemia. On the working basis, a corresponding serum GSDME detection kit can be directly transformed and developed to diagnose B lymphocytic leukemia, monitor the curative effect of B lymphocytic leukemia and evaluate the prognosis of B lymphocytic leukemia.

The invention discloses a cell immunofluorescence kit for determining phosphotyrosine adaptin ShcA antibody in human serum and a preparation method and application of the kit. The kit comprises a kit body, biological slide glass arranged in the box body, a coverslip and reagents in the kit body, the biological slide glass is coated with phosphotyrosine adaptin ShcA transfection cells, and the reagents include a fluorescence antibody reagent, a positive control, a negative control, a serum sample dilute solution, a condensed washing lotion and a mounting medium. The kit can be used as a diagnosis kit to detect the concentration of phosphotyrosine adaptin ShcA antibody in serum of patients with lupus nephritis, diabetic nephropathy or IgAN, MN and FSGS podocytopathy, the diagnosis specificity is 100, and the diagnosis sensitivity is 98.1%.

The invention discloses a diagnostic marker and application for distinguishing VCA-IgA positive normal people from nasopharyngeal carcinoma. The diagnostic marker combination consists of CCL3, MIF and VCA-IgA. The inventors found serum markers for the diagnosis of nasopharyngeal carcinoma: CCL3 and MIF from the protein chips of nasopharyngeal carcinoma patient serum and VCA-IgA positive population serum. The established model of CCL3, MIF combined with traditional nasopharyngeal carcinoma diagnostic marker VCA‑IgA can be used to distinguish VCA‑IgA positive normal population from nasopharyngeal carcinoma population, which improves diagnostic specificity and positive predictive value, reduces misdiagnosis, and provides Diagnosis of nasopharyngeal carcinoma provides a new way.

The invention provides a composition, an RPA-LFD kit and a method for rapidly detecting novel coronavirus. The composition, the RPA-LFD kit and the method have the following advantages: (1) the detection time is greatly shortened, the large-scale screening speed can be effectively improved, and the medical burden is relieved; and (2) double-gene target detection: the accuracy of SARS-CoV-2 detection is enhanced. And (3) convenience: the RPA reaction is carried out under a constant temperature condition, expensive professional instrument support is not needed, the LFD detection method is simple and easy to operate, professional service is not needed, and on-site rapid diagnosis can be realized. (4) the specificity is good, namely the primer can be distinguished from other animal coronaviruses and also can be distinguished from various subtype influenza viruses, and the specificity is relatively good.

The invention discloses application of an NUP98 gene as a glioma stem cell specific molecular marker and a glioblastoma treatment and prognosis target spot, NUP98 regulation and control of DNA damage repair is realized by combining with a transcription factor P65 and regulating and controlling the transcriptional activity of P65, and NUP98 overexpression is related to low survival rate of brain tumor patients. The NUP89 expression level is used as the marker of glioblastoma, the diagnosis accuracy of the NUP89 as the marker of glioblastoma is 93%, the diagnosis specificity is 100%, and the sensitivity is 85.4%.

The present invention provides methods for detecting pulmonary embolism. The method is based on the absolute count of platelet microparticles in plasma measured by standard flow cytometry as an adjunct to the diagnosis of pulmonary embolism. Through ROC curve analysis, the critical value of platelet microparticles for diagnosing pulmonary embolism was 716.90/μl, and the sensitivity and specificity at this critical value were 58.82% and 95.92%, respectively. The positive likelihood ratio was 14.41, and the negative likelihood ratio was 0.43. The positive predictive value was 93.75%, the negative predictive value was 69.12%, and the Youden's index was 54.74%. This method is a non-invasive operation, low cost, easy to carry out, and high specificity. It can further screen patients with positive D-dimer results in clinical practice, improve diagnostic specificity, and can be used as CTPA for patients with pulmonary embolism. The pre-examination evaluation method can reduce the adverse reactions caused by CTPA examination and reduce the burden on patients.